SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a sharp sell-off as a weak revenue outlook and concerns over its turnaround timeline in Greater China triggered institutional downgrades and automated selling cascades. While many community members are debating whether this marks a bottom for a long-term value play or a structural decline for a "woke" brand, others are capitalizing on the extreme oversold conditions to accumulate positions near decade-low price levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh its aggressive foundry expansion and capital structure moves against broader macroeconomic uncertainty driven by rising oil prices and geopolitical instability. The community remains deeply divided, with bulls pointing to the company's long-term manufacturing roadmap and potential for major customer announcements, while bears are focused on the stock's recent price volatility and sensitivity to regional tensions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is capturing significant attention as investors speculate on upcoming cannabis rescheduling news and federal pilot programs, with sentiment sharply divided between those betting on a short squeeze and critics pointing to the company's fiscal history and management. The stock remains a high-volatility battleground where community discussions are currently fixated on potential catalysts like shifting FDA policies and the implications of the company's upcoming earnings release.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors await the upcoming 10-K filing and earnings report, with the community closely tracking aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high among retail investors, who are actively discussing a potential valuation re-rating and the possibility of a short squeeze as the company works to resolve past narrative overhangs.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors weigh significant commercial potential from its recently approved drug, Yartemlea, against broader market pressure and aggressive short interest. The community is actively debating the stock's valuation, the impact of recent milestone payments from Novo Nordisk, and the potential for a short squeeze as traders watch for upcoming financial results and European regulatory updates.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI cloud infrastructure contract, which has triggered intense community debate over its low-float potential and possible short-squeeze dynamics. Investors are actively analyzing the company's valuation shift while discussing the impact of thin trading volume and the technical setup on the stock price.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware (RH) is experiencing extreme volatility as investors weigh the impact of ongoing tariff headwinds and a struggling housing market against the potential for a short squeeze. Market participants are heavily focused on the company's mixed earnings results and management's guidance, while the community remains sharply divided over the long-term viability of their luxury retail model in a high-interest rate environment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors debate the impact of potential memory compression technologies on future demand versus strong long-term AI-driven storage needs. The community remains deeply divided, with some traders actively shorting into the price swings while others emphasize valuation metrics and anticipate a rebound leading up to upcoming quarterly earnings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest positive Week 40 Phase 3 data, which demonstrates that sonelokimab sets a new standard in lesion control and durability for hidradenitis suppurativa. The community is actively debating the stock's significant long-term potential and clinical differentiation against incumbents, while many speculate that the upcoming institutional meetings and clinical milestones will catalyze a major repricing or buyout event.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is attracting heavy retail attention as traders speculate on a potential short squeeze, citing its history as a volatile, low-float runner and tight share structure. While the community is sharply divided between bullish expectations of a parabolic move and warnings of a pump-and-dump scheme, discussions remain intensely focused on cost-to-borrow data and the stock's tendency for rapid, high-volume spikes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global Health Publishes Postal Ballot Voting Results and Scrutinizer’s Report

Global Health Limited ( ($IN:MEDANTA) ) has provided an announcement. Global Health Limited, the operator of Medanta hospitals, is a listed Indian ...

Medanta Ranked India’s Best Hospital by Newsweek

• Named No. 1 in the country in list of ‘World’s Best Hospitals 2026’ • Among top global healthcare institutions for the seventh year running Gurugram, Haryana, India – Business Wire India Medanta – The Medicity, Gurugram, operated by Global Health Limited, has been ranked the No. 1 hospital in India in Newsweek’s prestigious ‘World’s […]

Cardiac care at a new era: Medanta showcases future of advanced heart treatment

Guwahati, January 28 : Cardiovascular diseases (CVDs) are a major and growing public health concern in Assam and have emerged as one of the leading causes of death in adults above the age of 40 years. Further, studies have indicated that people living in urban areas, including hilly regions, are increasingly vulnerable to CVDs, often well before they turn 40. Gurgaon-based Medanta - The Medicity, named the Best Private Hospital in India by Newsweek for six years in a row, leads the way in clinical research and advanced treatment options for a wide range of cardiac diseases, including Coronary Artery Disease (CAD) and Valvular Heart Disease (VHD). In a continued effort to improve medical care in the Northeastern states, Medanta brought its specialized expertise to Guwahati, with Dr. Praveen Chandra, Chairman, Interventional Cardiology, Cardiac Care at Medanta. The Medicity emphasizes the urgent need for early detection and management of advanced cardiac conditions. He further underscored Medanta's commitment to making world-class healthcare accessible to patients across the country.

Brief Healthcare: Primer: HeXun Biosciences (6986 TT) - Nov 2025 and more

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.

Brief Healthcare: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook and more

In this briefing: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 1. Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook For 3Q25, Classys reported in-line revenue of W83bn (+40% YoY) and below-consensus operating profit of W37.6bn (+30% YoY; OP margin of 45.3%). By category, aesthetic device revenue grew 30% YoY to W42.9bn, consumables revenue expanded 46% YoY to W37.3bn, and other revenue surged 310% YoY to W2.7bn. By region, domestic revenue climbed 57% YoY to W29.8bn, and overseas revenue increased 32% YoY to W53bn. Excluding Brazil, overseas revenue expanded 80% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... and more

In this briefing: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update 1. Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced. Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

In this briefing: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY Robust Execution and Order Pipeline to Fuel H2FY26 Growth: Wabag delivered a 19% YoY growth in revenue for Q2FY26, broadly meeting our estimates. Revenue recognition is typically skewed towards the second half of the year, indicating strong H2. The management mentioned that margins may vary on a quarterly basis, while the medium-term margin outlook remains intact. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

Brief Equities Bottom-Up: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 and more

In this briefing: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Calix’s Next Frontier: Can MDUs & International Push Boost Its Market Performance? 1. KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Macro Environment Outlook: The overall macro environment has shown a marked improvement, with uncertainty levels reducing by over 50% compared to Q4FY25. Europe displayed strong traction during the quarter as clients began transitioning their supply chains from local to more globally integrated ecosystems. Deal Wins/Pipeline: The company announced a major multi-year, multi-domain deal from a leading European OEM. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI and more

In this briefing: Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch HPG [BUY +38.0%] - Local, Global Tailwinds Support Solid Outlook VCB [BUY +25.3%] - EPS Growth to Improve in 2026-27; Attractive Valuation 1. Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Strong Operating Metrics: EOP REIT’s revenue rose 13% YoY to Rs 1,124 Cr, supported by portfolio expansion, strong leasing, and rent escalations. Total office space expanded 7% YoY to 40.9 Mn sq. ft., with new additions at Embassy Tech Village and Embassy Manyata. Healthy pre-leasing levels (97–100%) and lower vacancies lifted occupancy by 300 bps YoY to 90%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Uptick in Revenue and Profitability: Revenue, EBITDA, and Adjusted PAT increased by 9.1%, 25.7%, and 29.2% YoY, respectively, driven by strong demand in API, especially in the export market, leading to overall volume growth of 9% and negative variance of ~2%.

Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. It engages in the research and development activities related to drugs, surgery, medical devices and equipment. The company was founded on August 13, 2004 and is headquartered in Gurugram, India.

MEDANTA.NSE
Global Health Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest MEDANTA.NSE News

MEDANTA.NSEGlobal Health Ltd.